D型氨基酸氧化酶活性对于D-硝基精氨酸手性转化的影响

D-硝基精氨酸(D-NNA)可在大鼠体内发生手性转化生成其L型异构体,即L-NNA,后者可抑制一氧化氮合酶活性,减少一氧化氮生成,升高动脉血压.研究了D型氨基酸氧化酶(DAAO)在D-NNA手性转化中的作用及DAAO对不同(包括已报道在体内可发生手型转化的)D型氨基酸的选择活性.体内实验显示,DAAO的选择性抑制剂苯甲酸钠(400mg/kg)或肌酐(400mg/kg)均可在不同程度上抑制D-NNA升压作用,进一步研究发现,肾脏或肝脏DAAO酶液在外加DAAO后可提高D-NNA的手性转化约2倍,表明DAAO对于D-NNA在体内的手性转化是必需的.DAAO酶液对可在体内发生手性转化且转化率相似(30%～50%)的D型氨基酸(D-Phe,D-Leu和D-NNA)的选择性表现出显著差异(Kcat/Km相差可达约15倍左右),这从另一方面表明体内D-硝基精氨酸氧化是其发生手性转化的前提条件但非决定因素.     

D-氨基酸氧化酶研究进展

D-氨基酸氧化酶(D-amino acid oxidase:oxidoreductase, DAAO, EC 1.4.3.3)是一种以黄素腺嘌呤(FAD)为辅基的典型黄素蛋白酶类,可氧化D-氨基酸的氨基生成相应的酮酸和氨。在体内D-氨基酸的代谢中起着重要作用。主要介绍了D-氨基酸氧化酶的生理功能和应用、表达条件优化及通过定点突变对酶学性质的研究。     

D-氨基酸氧化酶与麦芽糖结合蛋白和透明颤菌血红蛋白的融合表达

D-氨基酸氧化酶(DAAO)是一种重要的工业酶。为了进一步提高DAAO在大肠杆菌中的可溶性和活性表达, 分别构建了麦芽糖结合蛋白(MBP)和透明颤菌血红蛋白与三角酵母DAAO (TvDAAO) 的N-端融合蛋白。其中, MBP融合蛋白MBP-TvDAAO在组成型(JM105/pMKC-DAAO)和诱导型菌株(JM105/pMKL-DAAO)中表达时, 目标蛋白的可溶性表达量分别达到全细胞蛋白表达量的28%以上和17%左右, 比无MBP融合的对照菌株BL21(DE3)/pET-DAAO分别提高3.7和1.8倍; 但其酶活水平显著下降。VHb融合蛋白VHb-TvDAAO在重组菌BL21(DE3)/pET-VDAAO中摇瓶诱导表达时, DAAO酶活达到了3.24 u/mL, 比对照菌株BL21(DE3)/pET-DAAO提高了约90%。     

D-氨基酸氧化酶与麦芽糖结合蛋白和透明颤菌血红蛋白的融合表达

D-氨基酸氧化酶(DAAO)是一种重要的工业酶。为了进一步提高DAAO在大肠杆菌中的可溶性和活性表达, 分别构建了麦芽糖结合蛋白(MBP)和透明颤菌血红蛋白与三角酵母DAAO (TvDAAO) 的N-端融合蛋白。其中, MBP融合蛋白MBP-TvDAAO在组成型(JM105/pMKC-DAAO)和诱导型菌株(JM105/pMKL-DAAO)中表达时, 目标蛋白的可溶性表达量分别达到全细胞蛋白表达量的28%以上和17%左右, 比无MBP融合的对照菌株BL21(DE3)/pET-DAAO分别提高3.7和1.8倍; 但其酶活水平显著下降。VHb融合蛋白VHb-TvDAAO在重组菌BL21(DE3)/pET-VDAAO中摇瓶诱导表达时, DAAO酶活达到了3.24 u/mL, 比对照菌株BL21(DE3)/pET-DAAO提高了约90%。     

荧光假单胞菌TM5-2中D-型氨基酸脱氢酶的鉴定和表达

从荧光假单胞菌TM5-2中得到一个含丙氨酸消旋酶基因的DNA片段(8.8kb),相邻的一个开读框(ORF)与甘氨酸/D-型氨基酸氧化酶基因相似。该ORF经过克隆、表达,并没有检测到甘氨酸/D-型氨基酸氧化酶的活性,推导而得的氨基酸序列与D-型氨基酸脱氢酶序列比较发现,ORF含有D-型氨基酸脱氢酶的所有重要的保守序列。经TTC培养基鉴定,其具有D-型氨基酸脱氢酶的活性,并对一系列D-型氨基酸有作用,最佳作用底物是D-组氨酸。     

内消旋-二氨基庚二酸脱氢酶关键氨基酸位点的改造提高对烷基取代2-酮酸的催化活力

【背景】高效实现D-氨基酸的生物合成一直是人们关注的热点。内消旋-二氨基庚二酸脱氢酶(meso-diaminopimelate dehydrogenase,DAPDH)能够直接催化2-酮酸和氨合成D-氨基酸。【目的】提高DAPDH对烷基取代2-酮酸的催化活力,并解释其催化机制。【方法】以来源于嗜热共生杆菌(Symbiobacteriumthermophilum)的内消旋-二氨基庚二酸脱氢酶(StDAPDH)为模板,在前期结构分析结合被选择位点突变结果的基础上,确定对H227位进行定点饱和突变,并以D-丙氨酸、D-2-氨基丁酸、D-正缬氨酸、D-谷氨酸为底物进行筛选。【结果】获得突变体H227Q和H227N。突变体H227Q对丙酮酸、2-氧代丁酸、2-氧代戊酸、2-酮戊二酸的比活力比野生型分别提高了10.9、11.5、8.6和7.6倍。动力学参数表明,突变体H227Q同时提高了酶对底物的亲和力及催化常数,使其对丙酮酸的催化效率(k_(cat)/K_m)相较于野生型提高了9.4倍。利用分子模拟技术分析突变体H227Q与产物氨基酸之间的相互作用表明,227位的谷氨酰胺通过与氨基酸的羧酸形成氢键,使得氨基酸产物Cα上的氢和辅酶烟酰胺环C4原子之间的距离缩短。【结论】利用定向进化技术提高DAPDH对烷基取代2-酮酸的催化活力,有助于开发新型的高效生物催化剂,这些工作也为下一步继续进行更具挑战性的D-氨基酸研究提供了基础。     

三角酵母D-氨基酸氧化酶基因在大肠杆菌中的克隆和表达

从三角酵母中提取总RNA ,反转录后进行PCR扩增得到D 氨基酸氧化酶 (D AminoAcidOxidase ,DAAO)基因 ,经测序可知 ,与文献中三角酵母的DAAO基因序列的同源性在 99%以上。将DAAO基因用NcoⅠ和BamHⅠ双酶切后 ,与相同酶切的大肠杆菌表达载体pET 2 8a连接 ,转化大肠杆菌TOP 1 0F′,并筛选得到重组质粒pET DAAO ,转化BL2 1 (DE3)感受态细胞 ,得到重组大肠杆菌BL2 1 (DE3) pET DAAO。对重组大肠杆菌中的D 氨基酸氧化酶进行了诱导表达 ,考察了诱导温度、菌浓度、诱导剂IPTG用量以及溶氧等因素对酶活的影响。结果表明 ,在 2 8℃、菌浓度 (OD6 0 0 ) 1 0、IPTG浓度 1mmol L时 ,DAAO酶活最高达 2 3 3U mL。研究进一步显示 ,用廉价无毒的乳糖可以替代IPTG进行诱导 ,当乳糖浓度为 2mmol L ,DAAO酶活可达 2 2 7U mL。经过补料分批培养和乳糖诱导 ,DAAO酶活可以达到 1 75U mL。     

D-氨基酸检测方法研究进展

自然界中存在20种基本氨基酸,除甘氨酸外都有两种互成镜像的对映体D-型和L-型。长期以来,人们认为D-氨基酸仅存在于微生物中,参与构成细胞壁肽聚糖层。但随着分析方法的发展,人们相继在多种生物体中(包括人体)发现了多种D-氨基酸,D-氨基酸才引起人们的高度重视,并意识到它们在医药、农药和食品等的组成中起着重要作用。D-氨基酸检测方法还需要不断发展与完善,以便更好地分析和认识D-氨基酸的重要作用。主要介绍酶法、气相层析法、高效液相法及生物传感器等检测方法。     

D-氨基酸氧化酶在不同毕赤酵母宿主菌中的表达比较

D-氨基酸氧化酶（DAAO）在转化头孢菌素C生产7-ACA和转化DL-氨基酸制备α-酮酸和L-氨基酸上起着重要的作用。采用DNA操作技术,将来源于三角酵母的DAAO基因连接至表达载体pPIC35K上,再将表达质粒pPIC35KDAAO分别整合P. pastoris的宿主细胞KM71和GS115,经筛选获得阳性重组菌PDK13（Mut^S）和PD27（Mut⁺）。重点对两种突变菌的表达条件进行了比较。结果显示：PDK13（Mut^S）株比PD27（Mut⁺）株消耗甲醇慢、诱导时间长,但对通气量要求低、表达水平高,摇瓶活力分别达到2700和2500 IU/L,14L发酵罐内活力分别达到10140和8463 IU/L。初步探索了DAAO对DL-苯丙氨酸的拆分,结果显示基因工程菌表达的DAAO具有良好的转化DL-苯丙氨酸制备苯丙酮酸和L-苯丙氨酸的能力。     

一种水稻蛋白酶抑制剂基因的克隆及其结构分析

参照水稻蛋白酶抑制剂部分氨基酸序列 ,利用水稻偏爱密码子设计引物 ,经 PCR扩增 ,从我国水稻 (Oryza sativa)品种“中花 8号”中克隆到一个长 40 8bp的基因。序列测定和分析表明 ,克隆到的是一个未见报道的新的水稻蛋白酶抑制剂基因 ,该基因编码了一个由 1 33个氨基酸组成 ,具有重复双功能结构域和以抑制胰蛋白酶为主的活性中心的包曼 -伯克 (Bowman- Birk)型蛋白酶抑制剂 ,该基因推导的氨基酸序列与大麦、小麦、豆类等的某些蛋白酶抑制剂的氨基酸序列具有较高的同源性 ,与该家族的水稻的一种胰蛋白酶抑制剂氨基酸全序列同源性高达 75%。     

D-Amino acid oxidase: Physiological role and applications

D-Amino acids play a key role in regulation of many processes in living cells. FAD-dependent D-amino acid oxidase (DAAO) is one of the most important enzymes responsible for maintenance proper level of D-amino acids. The most interesting and important data for regulation of the nervous system, hormone secretion, and other processes by D-amino acids as well as development of different diseases under changed DAAO activity are presented. The mechanism of regulation is complex and multi-parametric because the same enzyme simultaneously influences the level of different D-amino acids, which can result in opposing effects. Use of DAAO for diagnostic and therapeutic purposes is also considered.     

New biotech applications from evolved D-amino acid oxidases

D-Amino acid oxidase (DAAO) is a well-known flavoenzyme that catalyzes the oxygen-dependent oxidative deamination of amino acid D-isomers with absolute stereospecificity, which results in α-keto acids, ammonia and hydrogen peroxide. Recently, the extraordinary functional plasticity of DAAO has become evident; in turn, boosting research on this flavoprotein. Protein engineering has allowed for a redesign of DAAO substrate specificity, oxygen affinity, cofactor binding, stability, and oligomeric state. We review recent developments in utilizing DAAO, including as a biocatalyst for resolving racemic amino acid mixtures, as a tool for biosensing, and as a new mechanism of herbicide resistance. Perspectives for future biotechnological applications of this oxidative biocatalyst are also outlined.     

Is rat an appropriate animal model to study the involvement of D-serine catabolism in schizophrenia? Insights from characterization of D-amino acid oxidase

D-Amino acid oxidase (DAAO; EC1.4.3.3) has been proposed to play a main role in the degradation of D-serine, an allosteric activator of the N-methyl-D-aspartate-type glutamate receptor in the human brain, and to be associated with the onset of schizophrenia. To prevent excessive D-serine degradation, novel drugs for schizophrenia treatment based on DAAO inhibition were designed and tested on rats. However, the properties of rat DAAO are unknown and various in vivo trials have demonstrated the effects of DAAO inhibitors on d-serine concentration in rats. In the present study, rat DAAO was efficiently expressed in Escherichia coli. The recombinant enzyme was purified as an active, 40 kDa monomeric flavoenzyme showing the basic properties of the dehydrogenase-oxidase class of flavoproteins. Rat DAAO differs significantly from the human counterpart because: (a) it possesses a different substrate specificity; (b) it shows a lower kinetic efficiency, mainly as a result of a low substrate affinity; (c) it differs in affinity for the binding of classical inhibitors; (d) it is a stable monomer in the absence of an active site ligand; and (e) it interacts with the mammalian protein modulator pLG72 yielding a ~100 kDa complex in addition to the ~200 kDa one, as formed by the human DAAO. Furthermore, the concentration of endogenous D-serine in U87 glioblastoma cells was not affected by transfection with rat DAAO, whereas it was significantly decreased when expressing the human homologue. These results raise doubt on the use of the rat as a model system for testing new drugs against schizophrenia and indicate a different physiological function of DAAO in rodents and humans.     

Simple and rapid determination of the activity of recombinant D-amino acid oxidase in cephalosporin C bioconversion with use of a micro pO2 probe

Summary D-Amino acid oxidase (DAAO) genes were amplified from Trigonopsis variabilis and Rhodotorula gracilis by polymerase chain reactions. T. variabilis DAAO gene was cloned into a pUC19 vector. The expression of the T. variabilis DAAO was directly determined in permeabilized E. coli cells using a micro pO₂ probe. The micro pO₂ probe was sensitive enough to be suitable for a simple and rapid estimation of DAAO activity toward cephalosporin C.     

Characterization of human D-amino acid oxidase

D-Amino acid oxidase (DAAO) has been proposed to be involved in the oxidation of D-serine, an allosteric activator of the NMDA-type glutamate receptor in the brain, and to be associated with the onset of schizophrenia. The recombinant human DAAO was expressed in Escherichia coli and was isolated as an active homodimeric flavoenzyme. It shows the properties of the dehydrogenase-oxidase class of flavoproteins, possesses a low kinetic efficiency, and follows a ternary complex (sequential) kinetic mechanism. In contrast to the other known DAAOs, the human enzyme is a stable homodimer even in the apoprotein form and weakly binds the cofactor in the free form.     

D-amino acid oxidase: structure,catalytic mechanism,and practical application

D-Amino acid oxidase (DAAO) is a FAD-dependent enzyme that plays an important role in microbial metabolism, utilization of endogenous D-amino acids, regulation of the nervous system, and aging in mammals. DAAO from yeasts Rhodotorula gracilis and Trigonopsis variabilis are used to convert cephalosporin C into 7-aminocephalosporanic acid, the precursor of other semi-synthetic cephalosporins. This review summarizes the recent data on the enzyme localization, physiological role, gene cloning and expression, and the studies on the enzyme structure, stability, catalytic mechanism, and practical applications.Translated from Biokhimiya, Vol. 70, No. 1, 2005, pp. 51–67.Original Russian Text Copyright © 2005 by Tishkov, Khoronenkova.     

Synthesis of kojic acid derivatives as secondary binding site probes of d-amino acid oxidase

A series of kojic acid (5-hydroxy-2-hydroxymethyl-4H-pyran-4-one) derivatives were synthesized and tested for their ability to inhibit d-amino acid oxidase (DAAO). Various substituents were incorporated into kojic acid at its 2-hydroxymethyl group. These analogs serve as useful molecular probes to explore the secondary binding site, which can be exploited in designing more potent DAAO inhibitors.     

Discovery of isatin and 1H-indazol-3-ol derivatives as d-amino acid oxidase (DAAO) inhibitors

d-Amino acid oxidase (DAAO) is a potential target in the treatment of schizophrenia as its inhibition increases brain d-serine level and thus contributes to NMDA receptor activation. Inhibitors of DAAO were sought testing [6+5] type heterocycles and identified isatin derivatives as micromolar DAAO inhibitors. A pharmacophore and structure-activity relationship analysis of isatins and reported DAAO inhibitors led us to investigate 1H-indazol-3-ol derivatives and nanomolar inhibitors were identified. The series was further characterized by pK_a and isothermal titration calorimetry measurements. Representative compounds exhibited beneficial properties in in vitro metabolic stability and PAMPA assays. 6-fluoro-1H-indazol-3-ol (37) significantly increased plasma d-serine level in an in vivo study on mice. These results show that the 1H-indazol-3-ol series represents a novel class of DAAO inhibitors with the potential to develop drug candidates.     

TRIM59 interacts with ECSIT and negatively regulates NF-κB and IRF-3/7-mediated signal pathways

A series of inhibitors of d-amino acid oxidase (DAAO) are specific in blocking chronic pain, including formalin-induced tonic pain, neuropathic pain and bone cancer pain. This study used RNA interference technology to further validate the notion that spinal DAAO mediates formalin-induced pain. To target DAAO, a siRNA/DAAO formulated in polyetherimide (PEI) complexation and a shRNA/DAAO (shDAAO, with the same sequence as siRNA/DAAO after intracellular processing) expressed in recombinant adenoviral vectors were designed. The siRNA/DAAO was effective in blocking DAAO expression in NRK-52E rat kidney tubule epithelial cells, compared to the nonspecific oligonucleotides. Furthermore, multiple-daily intrathecal injections of both siRNA/DAAO and Ad-shDAAO for 7 days significantly inhibited spinal DAAO expression by 50-80% as measured by real-time quantitative PCR and Western blot, and blocked spinal DAAO enzymatic activity by approximately 60%. Meanwhile, both siRNA/DAAO and Ad-shDAAO prevented formalin-induced tonic phase pain by approximately 60%. Multiple-daily intrathecal injections of siRNA/DAAO and Ad-shDAAO also blocked more than 30% spinal expression of GFAP, a biomarker for the activation of astrocytes. These results further suggest that down-regulation of spinal DAAO expression and enzymatic activity leads to analgesia with its mechanism potentially related to activation of astrocytes in the spinal cord.